Fremanezumab is a calcitonin-gene related peptide (CGRP) pathway monoclonal antibody that is FDA approved for adults with both episodic and chronic migraine.

SCHD, thanks to its exposure to mature, dividend-paying companies, is withstanding the market shock better. Click here for ...